cbdMD Inc. posts Q1 net loss attributable to common shareholders of USD 0.32 million, down 68%

Reuters

Yesterday

cbdMD Inc. posts Q1 net loss attributable to common shareholders of USD 0.32 million, down 68%

cbdMD Inc. reported a 12% sequential increase in revenue for the first quarter ended December 31, 2025, reflecting continued stabilization of its core business. In December 2025, the company raised approximately USD 2.25 million in Series C preferred financing to improve liquidity and working capital. cbdMD completed the acquisition of Bluebird Botanicals in mid-January 2026, adding e-commerce operations and valuable intellectual property, including GRAS status for full-spectrum CBD formulations. Integration efforts are underway with a focus on operational efficiencies, cost synergies, and revenue optimization. The company also noted its strongest December and January performance in the past three years and expressed confidence in its positioning for improved operating results and sustainable profitability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. cbdMD Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602171610PR_NEWS_USPR_____CL89656) on February 17, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2612460115"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612460115\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612460115?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-18 05:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612460115","market":"fut","top_or_hot":-1,"title":"cbdMD Inc. posts Q1 net loss attributable to common shareholders of USD 0.32 million, down 68%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      cbdMD Inc. posts Q1 net loss attributable to common shareholders of USD 0.32 million, down 68%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        cbdMD Inc. reported a 12% sequential increase in revenue for the first quarter ended December 31, 2025, reflecting continued stabilization of its core business. In December 2025, the company raised approximately USD 2.25 million in Series C preferred financing to improve liquidity and working capital. cbdMD completed the acquisition of Bluebird Botanicals in mid-January 2026, adding e-commerce operations and valuable intellectual property, including GRAS status for full-spectrum CBD formulations. Integration efforts are underway with a focus on operational efficiencies, cost synergies, and revenue optimization. The company also noted its strongest December and January performance in the past three years and expressed confidence in its positioning for improved operating results and sustainable profitability.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. cbdMD Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602171610PR_NEWS_USPR_____CL89656) on February 17, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>cbdMD Inc. posts Q1 net loss attributable to common shareholders of USD 0.32 million, down 68%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\ncbdMD Inc. posts Q1 net loss attributable to common shareholders of USD 0.32 million, down 68%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-18 05:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      cbdMD Inc. posts Q1 net loss attributable to common shareholders of USD 0.32 million, down 68%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        cbdMD Inc. reported a 12% sequential increase in revenue for the first quarter ended December 31, 2025, reflecting continued stabilization of its core business. In December 2025, the company raised approximately USD 2.25 million in Series C preferred financing to improve liquidity and working capital. cbdMD completed the acquisition of Bluebird Botanicals in mid-January 2026, adding e-commerce operations and valuable intellectual property, including GRAS status for full-spectrum CBD formulations. Integration efforts are underway with a focus on operational efficiencies, cost synergies, and revenue optimization. The company also noted its strongest December and January performance in the past three years and expressed confidence in its positioning for improved operating results and sustainable profitability.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. cbdMD Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602171610PR_NEWS_USPR_____CL89656) on February 17, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL6vqqxW:1","article_id":"2612460115","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612460115","pubTimestamp":1771362633,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"cbdMD Inc. reported a 12% sequential increase in revenue for the first quarter ended December 31, 2025, reflecting continued stabilization of its core business. In December 2025, the company raised approximately USD 2.25 million in Series C preferred financing to improve liquidity and working capital. cbdMD completed the acquisition of Bluebird Botanicals in mid-January 2026, adding e-commerce operations and valuable intellectual property, including GRAS status for full-spectrum CBD formulations. Integration efforts are underway with a focus on operational efficiencies, cost synergies, and revenue optimization. The company also noted its strongest December and January performance in the past three years and expressed confidence in its positioning for improved operating results and sustainable profitability.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","YCBD":"cbdMD, Inc."},"translate_title":"cbdMD Inc.第一季度归属于普通股股东的净亏损为32万美元，下降68%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"YCBD":0.9},"content_text":"cbdMD Inc. posts Q1 net loss attributable to common shareholders of USD 0.32 million, down 68%\n    \n\n        cbdMD Inc. reported a 12% sequential increase in revenue for the first quarter ended December 31, 2025, reflecting continued stabilization of its core business. In December 2025, the company raised approximately USD 2.25 million in Series C preferred financing to improve liquidity and working capital. cbdMD completed the acquisition of Bluebird Botanicals in mid-January 2026, adding e-commerce operations and valuable intellectual property, including GRAS status for full-spectrum CBD formulations. Integration efforts are underway with a focus on operational efficiencies, cost synergies, and revenue optimization. The company also noted its strongest December and January performance in the past three years and expressed confidence in its positioning for improved operating results and sustainable profitability.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. cbdMD Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602171610PR_NEWS_USPR_____CL89656) on February 17, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}